• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Introduction to Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester (CAS No. 108128-21-8)

Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester, identified by the Chemical Abstracts Service Number (CAS No.) 108128-21-8, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrrolopyridazine class, a structural motif known for its diverse biological activities and potential applications in drug discovery. The presence of a carboxylic acid methyl ester functional group in its molecular structure enhances its versatility, making it a valuable scaffold for further chemical modifications and derivatization.

The structural framework of Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester consists of a fused ring system comprising a pyrrole ring and a pyridazine ring, interconnected at the 1-position of the pyrrole and the 2-position of the pyridazine. This unique arrangement contributes to its distinct electronic properties and reactivity, which are exploited in various synthetic pathways. The carboxylic acid methyl ester moiety at the 6-position provides a reactive site for further functionalization, enabling the attachment of other pharmacophoric groups or biomolecules.

In recent years, there has been a growing interest in heterocyclic compounds due to their prevalence in bioactive natural products and synthetic drugs. Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester has been studied for its potential role in modulating various biological pathways. Research has indicated that this compound exhibits inhibitory activity against certain enzymes and receptors, making it a promising candidate for the development of novel therapeutic agents. Specifically, studies have explored its interaction with enzymes involved in inflammation and cancer progression, suggesting its potential as an anti-inflammatory or anticancer agent.

One of the most compelling aspects of Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester is its synthetic accessibility. The compound can be synthesized through multi-step organic reactions that involve cyclization, condensation, and esterification processes. These synthetic routes have been optimized to ensure high yield and purity, making it feasible for large-scale production and further derivatization. The ability to modify its structure allows researchers to fine-tune its pharmacological properties, enhancing its efficacy and selectivity for specific targets.

The pharmacological profile of Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester has been investigated in several preclinical studies. These studies have demonstrated its ability to inhibit the activity of key enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are involved in the production of pro-inflammatory mediators. By targeting these enzymes, the compound may help mitigate inflammatory responses associated with various diseases. Additionally, preliminary data suggest that it may interfere with signaling pathways relevant to cancer cell proliferation and survival.

Another area of interest is the potential application of Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester in central nervous system (CNS) disorders. The compound's ability to cross the blood-brain barrier has been explored in experimental models, indicating its feasibility as a neuroactive drug. Research has focused on its effects on neurotransmitter systems involved in mood regulation and cognitive function. The findings suggest that it may have anxiolytic or antidepressant-like properties, although further studies are needed to confirm these effects in humans.

The chemical stability and solubility profile of Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester are also important considerations for pharmaceutical applications. Studies have shown that this compound is stable under standard storage conditions but may degrade under extreme pH or temperature conditions. Its solubility in common organic solvents makes it suitable for formulation into various dosage forms, including oral tablets and injectable solutions. These characteristics are crucial for ensuring the compound's shelf life and bioavailability.

In conclusion,Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester (CAS No. 108128-21-8) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activities. Its potential applications in treating inflammatory diseases, cancer, and CNS disorders make it an attractive candidate for further research and development. As our understanding of heterocyclic chemistry continues to evolve,Pyrrolo[1,2-b]pyridazine-6-carboxylic acid methyl ester is likely to play an increasingly important role in the discovery and development of novel therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)